Exploratory Evaluation of the Functional/Emotional Life Characteristics During the First Year of Ongoing Endocrine Adjuvant Treatment With Aromatase Inhibitors in Breast Cancer Patients With Reduced Bone Mineral Density (REBECCA-OST)

REBECCA-OST: Exploratory Evaluation of the Functional/Emotional Life Characteristics During the First Year of Ongoing Endocrine Adjuvant Treatment With Aromatase Inhibitors in Breast Cancer Patients (BCP) With Reduced Bone Mineral Density (BMD)

Exploratory evaluation of the Functional/Emotional Life characteristics during the first year of ongoing endocrine adjuvant treatment with Aromatase Inhibitors in Breast Cancer patients (BCP) with reduced Bone Mineral Density (BMD)

Study Overview

• Status: Recruiting
• Conditions: Breast Cancer; Osteopenia
• Intervention / Treatment: Diagnostic test: bone densitometry

Detailed Description

Many breast cancer therapies cause decreases in bone mineral density (BMD), as a result of oestrogen deprivation, a well-established risk factor for osteopenia (OST), osteoporosis and bone fractures. That leads to breast cancer patients having reduced bone mass, leading to higher risk for bone osteoporosis-related fractures, compared with age-matched healthy women, necessitating routine bone health assessments after a diagnosis of breast cancer. Such treatments include adjuvant endocrine therapies (e.g., tamoxifen and aromatase inhibitors) commonly used for hormone receptor-positive breast cancers, the most common type of breast cancer.

Additionally, chemotherapy or ablation of ovarian function (either medically or surgically) can lead to premature menopause among younger women and further reduce BMD5. Despite the advances in the pharmacology managing cancer treatment-induced osteopenia, the long-term efficacy of drug effects is debatable6 and there are numerous concerns about rare (but significant) side-effects of anti-resorptive drugs, particularly bisphosphonates. Those challenges necessitate additional research for the optimal OST management as a chronic breast cancer comorbidity.

Thus, the elucidation of the precise onset and progress of OST in patients and its interaction with lifestyle and high risk behaviours are now receiving increased research attention, aiming at the identification of novel patient management strategies to alleviate the chronic effects of the condition.

In order to counter the important life-effects of OST in breast cancer patients, current disease management schemes propose the integration of non-pharmacologic measures to maintain (or improve) optimal bone health, such as weight-bearing exercises and calcium and vitamin D supplementation. However, the lack of objective RWD on the effects of increased BMD on lifestyle is a serious challenge for the design of pragmatic and individualized patient management strategies. Indeed, lifestyle advice for increased physical activity are usually generic, lacking disease-specific knowledge, probably affecting the efficacy of exercise interventions. Overall, further evidence is required to optimise antiresorptive treatments, the use and choice of pharmacological agents, the duration of treatment and the potential of interaction with ongoing endocrine treatment.

Thus, the study will conduct the longitudinal comparison of Functional and Emotional Life Indices in Breast Cancer patients exhibiting significant reduction of BMD up to 12 months of adjuvant treatment with aromatase inhibitors, compared against matched BCPs with mild reduction of BMD. The study will use RWD to assess the safety and the effectiveness of aromatase inhibitor adjuvant endocrine therapy, with regards to osteopenia symptomatology over time. The study will consider data from 3 routine clinical evaluations (study month 0, 6 and 12) for the objective evaluation of BMD loss, complemented with continuous REBECCA use for 12 months. The collected data will include:

• Patient-reported measures: Medical and treatment history interview, project-related measurements, health-related quality of life, adjuvant treatment compliance estimation
• Medical examination: Gynecological physical and anthropometric examination, blood sampling, densitometry

For the REBECCA use, the participants will be trained in the use of the monitoring modules of the REBECCA platforms, facilitating the collection of real-world data (12 months). They will return (after 6 months) for a routine medical evaluation of osteopenia-related symptomatology and adjuvant treatment evaluation. They will complete a QoL questionnaire, and perform a structured interview, concerning mainly the appearance of new symptoms and adverse events or signs regarding bone issues, as well as a gynecological exam.

Blood tests will be collected, compliance to treatment will be evaluated and treatment satisfaction will be assessed.

The meeting will be repeated at 12 months, including a BMD examination

• Study Type: Observational
• Enrollment (Anticipated): 82

Contacts and Locations

Study Locations

• Spain
  • Valencia, Spain, 46010
    • Recruiting
    • Hospital Clinico Universitario de Valencia
    • Contact: Cristina Hernando, PhD; Phone Number: +34 689567412; Email: c.hernandomelia@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

• Sampling Method: Non-Probability Sample

Study Population

The study participant recruitment pool will be the whole population of BCPs undergoing endocrine adjuvant treatment (aromatase inhibitors) in the Oncology Department at Hospital Clínico de Valencia (Spain). As part of the ongoing patient follow-up, potential candidates with significant or milder reductions in BMD will be identified at study inclusion (early stages of adjuvant treatment period) based on comparisons with standard population BM measures (i.e., densitometry examination outcome: T-score lower than -1.0211). At this point, appropriate patients interested in the study will be informed about the study and written consents will be obtained.

All the potential participants will be female due to the nature of Breast Cancer

Description

Inclusion Criteria:

• Before patient registration, written informed consent must be given according to national and local regulations.
• Participants have had histologically proven stage I-III breast cancer undergoing endocrine treatment (with or without prior chemotherapy) no more than 12 months prior to randomization.
• Be between 18 and 75 years of age.
• Have increased life expectancy beyond the initial 3 months post-treatment initiation.
• Have the ability to understand protocol, participate in testing and willingness to sign a written informed consent.
• Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.

Exclusion Criteria:

• Patients already diagnosed with Osteopenia/Osteoporosis and already receiving BMD treatment (bisphosphonates or denosumab)
• Patients already diagnosed with osteopenia/osteoporosis who have already suffered a bone event related to decreased BMD
• Patients that are not willing to sign an informed consent form

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
OST; Patients with osteoporosis or severe osteopenia defined as having a significantly reduced BMD (T-score equal or lower than -1.5)	Diagnostic test: bone densitometry; bone densitometry every 6 month
Mild OST; Patients with mild-to-no reduction of BMD at the same post-treatment time point (T-score higher than -1.5)	Diagnostic test: bone densitometry; bone densitometry every 6 month

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Bone mineral density (BMD)	Chronic osteopenia, as a result of significant reduction of BMD, is expected to significantly negatively affect Functional Life characteristics in BCPs undergoing adjuvant endocrine aromatase inhibitors treatments in comparison to those with milder symptomatology. The association of the long-term outcomes of the PROM Index with the trajectory of reduced BMD-related symptomatology, as well as the Functional Life Index progression will be examined as an estimate of the safety and the effectiveness of the aromatase inhibitor adjuvant endocrine therapy. It is expected that the severity of reduced BMD-related symptomatology is associated with further deterioration of the Functional Life Index. Units: gr/cm^2	1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adjuvant treatment compliance	Adjuvant treatment compliance estimation (scale scored from 1 to 10)	1 year
Weight	Weight measurement (kg) as part of the anthropometric examination	1 year
Height	Height measurement (cm) as part of the anthropometric examination	1 year
C-Telopeptide concentration	C-Telopeptide concentration (pg/mL) from the blood samples extracted over the course of the study	1 year

Collaborators and Investigators

• Sponsor: Fundación para la Investigación del Hospital Clínico de Valencia

Publications and helpful links

Helpful Links

• Related Info

Study record dates

Study Major Dates

• Study Start (Actual): January 9, 2023
• Primary Completion (Anticipated): January 31, 2024
• Study Completion (Anticipated): June 30, 2024

Study Registration Dates

• First Submitted: October 7, 2022
• First Submitted That Met QC Criteria: March 9, 2023
• First Posted (Actual): March 22, 2023

Study Record Updates

• Last Update Posted (Actual): March 22, 2023
• Last Update Submitted That Met QC Criteria: March 9, 2023
• Last Verified: March 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Metabolic Diseases; Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Musculoskeletal Diseases; Bone Diseases; Breast Neoplasms; Bone Diseases, Metabolic
• Other Study ID Numbers: 2022/005-OST

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No